BIGBEAR
PHARMACEUTICALS
Upadacitinib is a highly potent and selective Janus kinase (JAK) inhibitor. It exerts its pharmacological effect by inhibiting the activity of JAK enzymes.
AuthenticGuaranteeFast DeliveryPrivacy NORTH CHICAGO, Ill., April 29, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved ···【Read More】
Update: 26 Feb,2026Source: Haiou HealthViews: 70
NORTH CHICAGO, Ill., Aug. 16, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.···【Read More】
Update: 26 Feb,2026Source: Haiou HealthViews: 70
NORTH CHICAGO, Ill., March 16, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved ···【Read More】
Update: 26 Feb,2026Source: Haiou HealthViews: 70
NORTH CHICAGO, Ill., Oct. 21, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announces that the U.S. Food and Drug Administration (FDA) has approved R···【Read More】
Update: 26 Feb,2026Source: Haiou HealthViews: 70
NORTH CHICAGO, Ill., May 18, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Ri···【Read More】
Update: 26 Feb,2026Source: Haiou HealthViews: 69
NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved Rinvo···【Read More】
Update: 26 Feb,2026Source: Haiou HealthViews: 69
Previously, Rinvoq was indicated for adults with moderately to severely active UC or CD who had an inadequate response or intolerance to one or more t···【Read More】
Update: 26 Feb,2026Source: Haiou HealthViews: 69
THURSDAY, Nov. 20, 2025 — New guidelines recommend doctors tackle Crohn’s disease head-on, calling for the use of cutting-edge drugs as early as possi···【Read More】
Update: 26 Feb,2026Source: Haiou HealthViews: 73
Copyright2024@ BIGBEAR All right reserved BIGBEAR
